港股異動|兆科眼科升近8% NVK002新藥上市申請獲受理
兆科眼科-B(6622.HK)今日盤中一度升7.84%至2.75港元,年內累升約1.3倍。兆科眼科昨日晚間公吿,中國國家藥品監督管理局最近受理公司核心產品之一、用於治療兒童近視加深的NVK002(硫酸阿托品滴眼液0.02%)的新藥上市申請。該新藥申請分類為II類創新藥。NVK002乃一項專利配方,成功解決低濃度阿托品的不穩性,此技術在全球均受到知識產權保護。按照灼識諮詢提供的資料,NVK002目前為全球用於治療近視加深的最先進阿托品候選藥物之一,目標患者組別最為廣泛,涵蓋3至17歲的兒童及青少年。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.